文献速递神经肿瘤

血脑屏障破坏后超选择性动脉内脑灌注现代化疗药物治疗脑肿瘤:现状与展望

Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
PubMed 文献 · J Neurooncol · 2020-02-19

本文综述了血脑屏障破坏后超选择性动脉内脑灌注(SSIACI)治疗脑肿瘤的临床前与临床证据,并回顾了正在开展的临床试验。多数试验仍使用甘露醇进行高渗性血脑屏障破坏,贝伐珠单抗动脉内给药已显示安全性及抗肿瘤疗效。作者认为动脉内给药可能显著影响脑肿瘤尤其是胶质母细胞瘤的治疗方式。

要点

  • SSIACI可在靶血管区域实现高浓度药物分布,并可能限制全身毒性。
  • 多数试验仍以甘露醇作为高渗性血脑屏障破坏的首选方法。
  • 贝伐珠单抗动脉内给药单用或联合化疗已显示安全性和抗肿瘤疗效。

核心结论

  • 动脉内药物递送可能显著影响脑肿瘤尤其是胶质母细胞瘤患者的治疗方式。
  • 随着技术改良与标准化、药物选择与剂型优化以及减轻治疗相关神经损伤方法的发展,动脉内治疗可能为脑肿瘤治疗带来显著获益。

研究设计与样本

  • 综述了支持血脑屏障破坏后超选择性动脉内脑灌注治疗脑肿瘤的临床前与临床证据,并回顾了正在开展的临床试验。

主要发现

  • 近期研究趋势倾向于采用SSIACI和神经毒性较低的化疗药物。
  • 多数试验仍使用甘露醇作为高渗性血脑屏障破坏的首选方法。
  • 近期临床前和初步人体研究显示,贝伐珠单抗动脉内给药单用及联合化疗均具有安全性和抗肿瘤疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,尚需进一步明确动脉内治疗脑肿瘤的临床疗效并完善其潜在应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Intra-arterial (IA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated IA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of IA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. METHODS: We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSIACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of IA therapy for the treatment of brain tumors. RESULTS: Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the IA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. CONCLUSION: IA drug delivery may significantly affect the way treatments are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of IA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, IA therapy may offer significant benefits for the treatment of brain tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. D'Amico RS, Khatri D, Reichman N, et al. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going. J Neurooncol. 2020. PMID: 32076934. doi:10.1007/s11060-020-03435-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。